P1119: CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY

• LI Zhi-Ming,
• Chuanxu Liu,
• Peng Sun,
• Shu Tian,
• Hao Ding,
• Rong Tao

Affiliations

LI Zhi-Ming

1 Sun Yat-sen University Cancer Center, Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

Chuanxu Liu

2 Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Department of Hematology, Shanghai, China

Peng Sun

1 Sun Yat-sen University Cancer Center, Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

Shu Tian

4 Eye & ENT Hospital, Fudan University, Department of Radiation Oncology, Shanghai, China

Hao Ding

4 Eye & ENT Hospital, Fudan University, Department of Radiation Oncology, Shanghai, China

Rong Tao

2 Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Department of Hematology, Shanghai, China